Cristóbal Carnero-Pardo

Cristóbal Carnero-Pardo

Auto-generated profile, based on publicly available information

Cristóbal Carnero-Pardo

FIDYAN Neurocenter, Granada, España

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in The Lancet Neurology
Verified
Journal Article
Open access
TAThaís Armangue
Thaís Armangue
MSMarianna Spatola
Marianna Spatola
AVAlexandru Vlagea
Alexandru Vlagea
SMSimone Mattozzi
Simone Mattozzi
MCMarc Cárceles-Cordon
Marc Cárceles-Cordon
AZAna Zabalza
Ana Zabalza
Herpes simplex encephalitis can trigger autoimmune encephalitis that leads to neurological worsening. We aimed to assess the frequency, symptoms, risk factors, and outcomes of this complication. We did a prospective observational study and retrospective analysis. In the prospective observational part of this study, we included patients with herpes simplex encephalitis diagnosed by neurologists, paediatricians, or infectious disease specialists in 19 secondary and tertiary Spanish centres (Cohort A). Outpatient follow-up was at 2, 6, and 12 months from onset of herpes simplex encephalitis. We studied another group of patients retrospectively, when they developed autoimmune encephalitis after herpes simplex encephalitis (Cohort B). We compared demographics and clinical features of patients who developed autoimmune encephalitis with those who did not, and in patients who developed autoimmune encephalitis we compared these features by age group (patients ≤4 years compared with patients >4 years). We also used multivariable binary logistic regression models to assess risk factors for autoimmune encephalitis after herpes simplex encephalitis. Between Jan 1, 2014, and Oct 31, 2017, 54 patients with herpes simplex encephalitis were recruited to Cohort A, and 51 were included in the analysis (median age 50 years [IQR 5-68]). At onset of herpes simplex encephalitis, none of the 51 patients had antibodies to neuronal antigens; during follow-up, 14 (27%) patients developed autoimmune encephalitis and all 14 (100%) had neuronal antibodies (nine [64%] had NMDA receptor [NMDAR] antibodies and five [36%] had other antibodies) at or before onset of symptoms. The other 37 patients did not develop autoimmune encephalitis, although 11 (30%) developed antibodies (n=3 to NMDAR, n=8 to unknown antigens; p<0·001). Antibody detection within 3 weeks of herpes simplex encephalitis was a risk factor for autoimmune encephalitis (odds ratio [OR] 11·5, 95% CI 2·7-48·8; p<0·001). Between Oct 7, 2011, and Oct 31, 2017, there were 48 patients in Cohort B with new-onset or worsening neurological symptoms not caused by herpes simplex virus reactivation (median age 8·8 years [IQR 1·1-44·2]; n=27 male); 44 (92%) patients had antibody-confirmed autoimmune encephalitis (34 had NMDAR antibodies and ten had other antibodies). In both cohorts (n=58 patients with antibody-confirmed autoimmune encephalitis), patients older than 4 years frequently presented with psychosis (18 [58%] of 31; younger children not assessable). Compared with patients older than 4 years, patients aged 4 years or younger (n=27) were more likely to have shorter intervals between onset of herpes simplex encephalitis and onset of autoimmune encephalitis (median 26 days [IQR 24-32] vs 43 days [25-54]; p=0·0073), choreoathetosis (27 [100%] of 27 vs 0 of 31; p<0·001), decreased level of consciousness (26 [96%] of 27 vs seven [23%] of 31; p<0·001), NMDAR antibodies (24 [89%] of 27 vs 19 [61%] of 31; p=0·033), and worse outcome at 1 year (median modified Rankin Scale 4 [IQR 4-4] vs 2 [2-3]; p<0·0010; seizures 12 [63%] of 19 vs three [13%] of 23; p=0·001). The results of our prospective study show that autoimmune encephalitis occurred in 27% of patients with herpes simplex encephalitis. It was associated with development of neuronal antibodies and usually presented within 2 months after treatment of herpes simplex encephalitis; the symptoms were age-dependent, and the neurological outcome was worse in young children. Prompt diagnosis is important because patients, primarily those older than 4 years, can respond to immunotherapy. Mutua Madrileña Foundation, Fondation de l'Université de Lausanne et Centre Hospitalier Universitaire Vaudois, Instituto Carlos III, CIBERER, National Institutes of Health, Generalitat de Catalunya, Fundació CELLEX.

1 February 2001 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
PPPau Pastor
Pau Pastor
EPEliana Pastor
Eliana Pastor
RVRosario Vela
Rosario Vela
GAGuillem Amer
Guillem Amer
ETEduardo Tolosa
Eduardo Tolosa
TGTeresa García
Teresa García

1 October 2014 in Neurología
Verified
Journal Article
Closed access
CCC. Carnero-Pardo
C. Carnero-Pardo

1 February 2015 in Journal of Periodontology
Verified
Journal Article
Closed access
JGJosé A. Gil‐Montoya
José A. Gil‐Montoya
ISInes Sanchez‐Lara
Ines Sanchez‐Lara
CCCristobal Carnero‐Pardo
Cristobal Carnero‐Pardo
FFFrancisco Fornieles
Francisco Fornieles
JMJuan Montes
Juan Montes
MBManuel Bravo
Manuel Bravo
Background: Dementia is a multi‐etiologic syndrome characterized by multiple cognitive deficits but not always by the presence of cognitive impairment. Cognitive impairment is associated with multiple non‐modifiable risk factors but few modifiable factors. Epidemiologic studies have shown an association between periodontitis, a potentially modifiable risk factor, and cognitive impairment. The objective of this study is to determine whether clinical periodontitis is associated with the diagnosis of cognitive impairment/dementia after controlling for known risk factors, including age, sex, and education level.Methods: A case‐control study was conducted in Granada, Spain, in two groups of dentate individuals aged >50 years: 1) cases with a firm diagnosis of mild cognitive impairment or dementia of any type or severity and 2) controls with no subjective memory loss complaints and a score >30 in the Phototest cognitive test (screening test for cognitive impairment). Periodontitis was evaluated by measuring tooth loss, plaque and bleeding indexes, probing depths, and clinical attachment loss (AL).Results: The study included 409 dentate adults, 180 with cognitive impairment and 229 without. A moderate and statistically significant association was observed between AL and cognitive impairment after controlling for age, sex, education level, oral hygiene habits, and hyperlipidemia (P = 0.049). No significant association was found between tooth loss and cognitive impairment.Conclusion: Periodontitis appears to be associated with cognitive impairment after controlling for confounders such as age, sex, and education level.

14 September 2015 in Neurología
Verified
Journal Article
Closed access
PDF file
JOJ. Olazarán
J. Olazarán
MHM.C. Hoyos-Alonso
M.C. Hoyos-Alonso
TST. del Ser
T. del Ser
ABA. Garrido Barral
A. Garrido Barral
JCJ.L. Conde-Sala
J.L. Conde-Sala
CCC. Carnero-Pardo
C. Carnero-Pardo

29 July 2011 in BMC Neurology
Verified
Journal Article
Open access
PDF file
CCCristobal Carnero-Pardo
Cristobal Carnero-Pardo
BEBeatriz Espejo-Martinez
Beatriz Espejo-Martinez
SLSamuel Lopez-Alcalde
Samuel Lopez-Alcalde
MEMaria Espinosa-Garcia
Maria Espinosa-Garcia
CSCarmen Saez-Zea
Carmen Saez-Zea
JNJose L Navarro-Espigares
Jose L Navarro-Espigares
To assess and compare the effectiveness and costs of Phototest, Mini Mental State Examination (MMSE), and Memory Impairment Screen (MIS) to screen for dementia (DEM) and cognitive impairment (CI).